Sector
PharmaceuticalsOpen
₹6,090Prev. Close
₹6,172.5Turnover(Lac.)
₹302.33Day's High
₹6,219Day's Low
₹6,09052 Week's High
₹7,60052 Week's Low
₹4,902Book Value
₹425.59Face Value
₹10Mkt Cap (₹ Cr.)
14,157.69P/E
37.31EPS
164.93Divi. Yield
1.9The board has proposed a final dividend of ₹117 per equity share (face value of ₹10), subject to shareholders approval at the next Annual General Meeting.
Y/e 31 Mar( In .Cr) | Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 |
---|---|---|---|---|
Equity Capital | 23 | 23 | 23 | 23 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 837.6 | 992.5 | 1,252.8 | 2,202.6 |
Net Worth | 860.6 | 1,015.5 | 1,275.8 | 2,225.6 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Dec-2021 | Dec-2019 | Dec-2018 | Dec-2017 |
---|---|---|---|---|
Revenue | 2,956.6 | 3,070.6 | 2,770.8 | 2,463.6 |
yoy growth (%) | -3.71 | 10.81 | 12.46 | 4.08 |
Raw materials | -1,306.8 | -1,347.4 | -1,145.9 | -1,004.1 |
As % of sales | 44.19 | 43.88 | 41.35 | 40.75 |
Employee costs | -433.9 | -449.7 | -406.8 | -368.5 |
Y/e 31 Mar( In .Cr) | Dec-2021 | Dec-2019 | Dec-2018 | Dec-2017 |
---|---|---|---|---|
Profit before tax | 768.4 | 659.2 | 609.8 | 514.6 |
Depreciation | -66.7 | -99.9 | -102.7 | -102.2 |
Tax paid | -313.2 | -185.7 | -229.2 | -188.6 |
Working capital | -30.59 | 457.2 | 126.6 | -231.1 |
Other operating items |
Y/e 31 Mar | Dec-2021 | Dec-2019 | Dec-2018 | Dec-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -3.71 | 10.81 | 12.46 | 4.08 |
Op profit growth | 14.6 | 6.7 | 16.06 | 0.39 |
EBIT growth | 16.78 | 8.02 | 18.38 | 6.83 |
Net profit growth | 128 | 8.82 | 16.74 | 7.16 |
Particulars (Rupees in Crores.) | Dec-2024 | Dec-2023 | Dec-2004 | Dec-2003 |
---|---|---|---|---|
Gross Sales | 2,013.2 | 1,996.1 | 794.09 | 707.2 |
Excise Duty | 0 | 0 | 55.7 | 49.9 |
Net Sales | 2,013.2 | 1,996.1 | 738.4 | 657.29 |
Other Operating Income | 0 | 0 | 0 | 0 |
Other Income | 116.1 | 317.3 | 26.6 | 21.29 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,687.4 | 94.51 | 4,04,767.81 | 2,000.46 | 0.95 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,725 | 80.79 | 1,78,467.89 | 667 | 0.45 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,502.8 | 24.63 | 1,21,323.17 | 1,485.4 | 1.07 | 4,254.47 | 397.42 |
Dr Reddys Laboratories Ltd DRREDDY | 1,362.7 | 21.27 | 1,13,756.67 | 1,200.7 | 0.59 | 5,546.3 | 345.79 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,258.8 | 57.91 | 1,10,340.1 | 474 | 0.98 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Independent Directo
Aditya Narayan
Independent Director
Usha Thorat
Non Executive Director
Vaibhav KARANDIKAR
Independent Director
Rahul Bhatnagar
Managing Director
Rodolfo Hrosz
Company Sec. & Compli. Officer
Radhika Shah
Whole Time Director
Renee Amonkar
Whole Time Director & CFO
Rachid Ayari
Sanofi Hse 117-B Saki Vihar Rd,
L&T Business Park Powai,
Maharashtra - 400072
Tel: 91-22-28032000
Website: http://www.sanofiindialtd.com
Email: igrc.sil@sanofi.com
C-101 247 Park,
L B S Marg, Vikhroli West,
Mumbai-400083
Tel: 91-22-49186000
Website: www.linkintime.co.in
Email: paytm.ipo@linkintime.co.in
Summary
Sanofi India Limited, was initially incorporated as Aventis Pharma Limited in May, 1956. The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012. The Company i...
Read More
Reports by Sanofi India Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.